Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast,prostate and lung cancer |
| |
| Affiliation: | 1. Menzies Centre for Health Policy, Sydney School of Public Health University of Sydney, Australia;2. Department of Public Health Sciences, University of Rochester, School of Medicine and Dentistry, United States;3. School of Public Health and Community Medicine, University of New South Wales, Australia;1. Faculty of Health Sciences of the University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal;2. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, SE 701 82 Örebro, Sweden;3. Department of Statistics, Örebro University, 701 82, Örebro, Sweden;4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE 171 77, Stockholm, Sweden;5. Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, SE 171 76 Stockholm, Sweden;6. Department of Epidemiology and Public Health, University College, WC1E 6BT London, UK;1. Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark;2. University Clinic for Innovative Patient Pathways, Silkeborg Hospital, Department of Clinical Medicine, Aarhus University, Falkevej 1-3, DK-8600 Silkeborg, Denmark;1. Department of Oncology, Queen’s University, Kingston, Canada;2. Department of Surgery, Queen’s University, Kingston, Canada;3. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Canada;1. Registre des cancers du Bas-Rhin, U1113, FMTS, Université de Strasbourg, 4 rue Kirschleger, 67085 Strasbourg, France;2. Service de santé publique, Hôpitaux Universitaires de Strasbourg, 1 place de l’hôpital, 67091 Strasbourg, France;3. Registre des cancers de la Manche, Centre Hospitalier Public du Cotentin, 46 rue du Val de Saire, 50102 Cherbourg-Octeville, France;4. Registre des tumeurs de l''Hérault, Centre de Recherche, 208 rue des Apothicaires, 34298 Montpellier, France;5. Registre général des tumeurs du Calvados, Cancers & Préventions – U1086 Inserm, Centre François Baclesse, Avenue du Général Harris BP 5026, 14076 Caen, France;6. Registre des tumeurs du Doubs et du Territoire de Belfort, EA3181, Centre Hospitalier Régional Universitaire, 25030 Besançon, France;7. Registre des cancers du Tarn, 1, rue Lavazière, BP 37, 81001 Albi cedex, France;8. Institut Claudius Regaud, Centre régional de lutte contre le cancer, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France;9. Registre des hémopathies malignes de Basse-Normandie, Unité Fonctionnelle Hospitalo-Universitaire n°0350, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, 14033 Caen, France;10. Registre des cancers de l’Isère, CHU de Grenoble, Pavillon E BP 217, 38043 Grenoble 9, France;11. Registre du cancer de la Somme, Service Épidémiologie Hygiène et Santé Publique, CHU Nord, 80054 Amiens, France;12. Service d’épidémiologie et de biostatistique, Centre Paul Strauss, 3 rue de la Porte de l’hôpital, 67065 Strasbourg, France;1. University of Sydney, Australia;2. University of New South Wales, Australia;1. Department of Epidemiology, University of Alabama at Birmingham, Birmingham AL, United States;2. Comprehensive Cancer Center. University of Alabama at Birmingham, Birmingham AL, United States;3. University of Northern Colorado Cancer Rehabilitation Institute, Greeley, CO, United States;4. School of Social Work, College of Health and Human Sciences, Colorado State University, Fort Collins, CO, United States |
| |
| Abstract: | BackgroundOlder people represent increasing proportions of the population with cancer. To understand the representivity of cancer treatments in older people, we performed a systematic literature review using PRISMA guidelines of the age distribution of clinical trial participants for three leading cancer types, namely breast, prostate, and lung.MethodsWe used PubMed to identify articles detailing meta or pooled-analyses of phase III, randomised controlled trials (RCTs) of survival for breast, prostate and lung cancer, published ≤5 years from 2016. We compared the age distribution of participants to that of these cancers for “More developed regions”.Results4993 potential papers were identified, but only three papers on breast cancer, three on lung cancer, and none on prostate cancer presented the age distribution of their participants. Except for one paper of breast cancer, participants ≥70 years in all other papers were underrepresented.ConclusionsWe recommend the age distribution of patients be clearly reported in all clinical trials, as per guidelines. Clinical trials ought to be more representative of the populations most affected by the disease for which treatments are being tested. This should lead to better knowledge of effectiveness of treatments and better translation of trial results to optimal care of older cancer patients. |
| |
| Keywords: | Clinical trials Phase III Representivity Cancer and ageing Cancer treatment |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
